Scientists test nanoparticle vaccine against painful mosquito virus
NCT ID NCT07394426
Summary
This is a first-in-human study to check the safety and immune response of a new experimental vaccine against chikungunya virus. The trial will enroll 40 healthy adults aged 18-60 who will receive two injections six weeks apart. Researchers will closely monitor participants for side effects and measure if the vaccine triggers an immune response against the virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.